On average it takes at least 10 years to get a drug to market from pre-discovery to marketplace; the price of a successful drug exceeds $2.6B when accounting for the cost of failures. Clinical trials can take anywhere from six-to-seven years alone. Speeding up this process provides hope to the millions of patients suffering from various conditions as well as alleviates the burden on the healthcare system that has to manage the increasing costs of drug development. Lindus Health is building an operating system for clinical research that will allow the research needed for clinical trials to be centralized and modernized. The company projects that shifting away from a pen and paper model with limited technology will unleash next-generation innovation in healthcare as companies can be nimbler than ever before and without the need for the heavy capital requirements that legacy clinical trials required, allowing more participants in the ecosystem. The recently-launched venture is already partnered with leading healthcare research institutions like King’s College London, Imperial College, London, UCL, and the University of Oxford. LondonTechWatch caught up with Lindus Health Cofounder Michael Young to learn more about the inspiration of the company, upcoming strategic plans, the positioning, and recent round of funding from investors that include Firstminute Capital, Presight Capital, Seedcamp, Hambro Perks, Amino Collective, Mehdi Ghissassi, Alex Zhavoronkov, Marc Warner, James Dacombe , Henry de Zoete, and Vishal Gulati.